Frontiers Clinical and Translational Science Institute at the University of Kansas

堪萨斯大学前沿临床与转化科学研究所

• 批准号: 10674055
• 负责人: Mario Castro
• 金额: $ 381.79万
• 依托单位: UNIVERSITY OF KANSAS MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-09-07 至 2027-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10674055
• 关键词: Acceleration; Address; Adopted; AstraZeneca COVID-19 vaccine; Biological Markers; COVID testing; COVID-19; COVID-19 pandemic; COVID-19 pathogenesis; COVID-19 therapeutics; COVID-19 treatment; COVID-19 vaccine evaluation; Career Mobility; Child; Cities; Clinical Informatics; Clinical Research; Clinical Sciences; Clinical Trials; Clinical Trials Unit; Collaborations; Communication; Communities; Conduct Clinical Trials; County; Creativeness; Data; Data Set; Decision Making; Development; Diagnostic; Discipline; Disease; Diverse Workforce; Ensure; Environment; Equity; Exclusion; Fostering; Funding; Genomic medicine; Genomics; Goals; Grant; Health; Health Priorities; Health system; Healthcare; Healthcare Systems; Hospitals; Human; Individual; Informatics; Infrastructure; Institution; Intervention; Intervention Trial; Investments; Kansas; Knowledge; Latinx; Leadership; Learning; Longevity; Maps; Measures; Medical center; Methods; Midwestern United States; Mission; Missouri; Patients; Population; Population Heterogeneity; Public Health; RADx; Rare Diseases; Research; Research Design; Research Methodology; Research Personnel; Resources; Rural; Rural Community; SARS-CoV-2 infection; Safety; Science; Structure; TNFSF15 gene; Therapeutic Intervention; Training; Translating; Translational Research; Underrepresented Populations; Underserved Population; Universities; Vision; Work; Workforce Development; career development; catalyst; collaborative approach; community organizations; coronavirus disease; design; experience; frontier; health care quality; health disparity; health equity; human subject; improved; innovation; multi-component intervention; nano; novel; patient advocacy group; point of care; preventive intervention; programs; recruit; response; symposium; tool; vaccine trial

Contact PD/PI: Castro, Mario OVERALL PROJECT SUMMARY/ABSTRACT The Frontiers Clinical and Translational Science Institute at the University of Kansas (Frontiers) has been a catalyst for clinical and translational research (CTR) across the Kansas City region. The vision of Frontiers 3.0 is to transform the way we do CTR and ensure that research is rapidly translated to the point of care in a way that improves health for underserved and excluded populations, especially those in rural communities. To do so, we have expanded Frontiers 3.0 partners to include multiple academic institutions, healthcare systems, and community organizations and patient advocacy groups across Kansas and western Missouri. Our new shared leadership structure balances power across institutions. The overall aims of Frontiers are: Aim 1. Train a diverse workforce that leverages multiple disciplines, frameworks and approaches to stimulate creative, responsive and impactful T1-T4 clinical and translational research. Frontiers cores and its KL2 and TL1 programs provide high quality training, assistance in research design and implementation, guidance in applying for grants, and support for career advancement for all levels translational research trainees. In Frontiers 3.0 we emphasize identifying and supporting investigators from underrepresented groups and those with a research focus on underserved and excluded populations. Aim 2. Collaborate and engage with underserved and excluded communities to ensure that clinical and translational research is responsive to their priorities and achieves greater health equity. Frontiers 3.0 hosts Design Studios, Fieldwork Nano-experiences, Story-telling sessions, Community Co- Investigator Human Subjects Training and Conferences to support collaborations between researchers and patients, communities, and stakeholders. New advisory groups of community partners and community- engaged researchers provide guidance at all levels of Frontiers decisionmaking. We expand our novel efforts to understand and address COVID-19 across the lifespan and among underserved and excluded groups. Aim 3. Drive innovative, quality, and efficient clinical and translational research across the lifespan that harnesses novel informatics, genomics, team science and implementation methods to enhance delivery of high-quality healthcare in the region. Frontiers reduces barriers to entering CTR by providing unparalleled comprehensive support that minimizes regulatory burden and expedites research. New cores provide entre to tools and data for pursuing genomic medicine and help investigators access and analyse rich datasets available via clinical informatics. New leadership in Team Science will map investigator networks, identify gaps, and introduce individual and team- level interventions to help investigators build and maintain effective teams. Frontiers will accelerate CTR in the Midwest and build a workforce that attends to health priorities for the rural, underserved, and excluded. Our discoveries and new tools will contribute to knowledge for the nation. Project Summary/Abstract Page 302 Contact PD/PI: Castro, Mario OVERALL NARRATIVE The Frontiers Clinical and Translational Sciences Institute at the University of Kansas is a regional initiative involving academic institutions, healthcare systems and community organizations that addresses the clinical and translational research needs of Kansas and western Missouri. Frontiers supports high quality translational science and clinical research locally, regionally and nationally. It fosters innovation in research methods, training, and career development of investigators committed to improving health and achieving health equity across the lifespan, with a focus on underserved and excluded populations.

联系PD/PI：Castro、Mario 总体项目总结/摘要 堪萨斯大学前沿临床和转化科学研究所（前沿）一直是一个 催化剂的临床和转化研究（CTR）在整个堪萨斯城地区。关于Frontiers 3.0 是改变我们进行CTR的方式，并确保研究能够快速转化为护理点， 这改善了服务不足和受排斥人口的健康，特别是农村社区的人口。做 因此，我们扩大了Frontiers 3.0合作伙伴，包括多个学术机构，医疗保健系统， 社区组织和病人倡导团体横跨堪萨斯和西部密苏里州。我们的新共享 领导结构平衡各机构的权力。Frontiers的总体目标是： 目标1。培训多元化的员工队伍，利用多个学科、框架和方法， 促进创造性、响应性和有影响力的T1-T4临床和转化研究。 Frontiers核心及其KL 2和TL 1项目提供高质量的培训、研究设计援助， 实施、申请赠款指导和支持各级职业发展 研究实习生。在Frontiers 3.0中，我们强调识别和支持来自 代表性不足的群体和研究重点是得不到充分服务和受排斥的人口的群体。 目标二。与服务不足和受排斥的社区合作，确保临床和 转化型研究顺应了他们的优先事项，并实现了更大的卫生公平。 Frontiers 3.0举办设计工作室，实地考察纳米体验，讲故事会议，社区合作 研究者人类受试者培训和会议，以支持研究者和 患者、社区和利益相关者。新的社区伙伴和社区咨询小组- 参与的研究人员为前沿的各级决策提供指导。我们扩大我们的创新努力 了解和应对整个生命周期以及服务不足和受排斥群体中的COVID-19。 目标3.在整个生命周期内推动创新、优质和高效的临床和转化研究， 利用新颖的信息学、基因组学、团队科学和实施方法， 为该地区提供高质量的医疗服务。 Frontiers通过提供无与伦比的全面支持来减少进入CTR的障碍， 监管负担和加速研究。新的核心为追求基因组学提供了工具和数据 帮助研究人员访问和分析通过临床信息学提供的丰富数据集。新 团队科学的领导将绘制研究者网络图，找出差距，并介绍个人和团队- 各级干预措施，以帮助调查人员建立和维持有效的团队。 Frontiers将加速中西部的CTR，并建立一支关注农村卫生优先事项的劳动力队伍， 得不到充分的服务，被排斥在外我们的发现和新工具将为国家的知识作出贡献。 项目摘要/摘要第302页 联系PD/PI：Castro、Mario 整体叙事 堪萨斯大学的前沿临床和转化科学研究所是一个 涉及学术机构、保健系统和社区的区域倡议 满足堪萨斯临床和转化研究需求的组织， 密苏里州西部。前沿支持高质量的转化科学和临床研究 地方、区域和国家。它促进研究方法、培训和职业的创新 发展致力于改善健康和实现健康公平的调查人员 寿命，重点是服务不足和受排斥的人口。